Erin Butler - 25 Jul 2025 Form 4 Insider Report for ImageneBio, Inc. (IMA)

Role: Principal Accounting Officer
Signature: /s/ Erin Butler
Issuer symbol: IMA
Transactions as of: 25 Jul 2025
Transactions value $: $0
Form type: 4
Filing time: 29 Jul 2025, 19:02:36 UTC
Previous filing: 07 Feb 2023
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Butler Erin	Principal Accounting Officer	C/O IMAGENEBIO, INC., 12526 HIGH BLUFF DRIVE, SUITE 345, SAN DIEGO	/s/ Erin Butler	29 Jul 2025	0001940413

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMA	Common Stock	Award		+3.05K			3.05K	25 Jul 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMA	Employee Stock Option (right to buy)	Award		+3.81K			3.81K	25 Jul 2025	Common Stock	3.81K	$4.59	Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Received in exchange for 1,000,000 ordinary shares of Inmagene Biopharmaceuticals ("Legacy Inmagene") pursuant to Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Merger Sub I, a wholly-owned subsidiary of the Issuer ("Merger Sub I"), Merger Sub II, a wholly-owned subsidiary of the Issuer ("Merger Sub II") and Legacy Inmagene (the "Merger Agreement").
F2	Under the terms of the Merger Agreement, on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the "Merger"), with Legacy Inmagene surviving the Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the Merger as a wholly-owned subsidiary of the Issuer (the "Second Merger" and together with the First Merger, the "Merger"). Upon the closing of the First Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. to ImageneBio, Inc.
F3	25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
F4	Received in exchange for a stock option to acquire 1,250,000 shares of common stock of Legacy Inmagene with the exercise price of $0.014 per share pursuant to the Merger Agreement.